Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Legend Biotech ( (LEGN) ) has issued an announcement.
On June 5, 2025, Legend Biotech Corporation announced the appointment of Peter Salovey, Ph.D., as Lead Independent Director, effective immediately. Dr. Salovey, who has been an independent director since August 2024, is expected to leverage his extensive leadership experience to enhance communication among the Board of Directors, management, and shareholders, potentially guiding the company through strategic growth phases.
The most recent analyst rating on (LEGN) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s overall score reflects strong revenue growth and strategic plans for profitability, but is tempered by current financial losses and negative technical indicators. The positive outlook from the earnings call adds optimism, but cash flow issues and valuation concerns weigh down the score.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel therapies. The company is known for its innovative approaches in the field of cell therapy, aiming to address unmet medical needs in the global market.
Average Trading Volume: 1,552,080
Technical Sentiment Signal: Sell
Current Market Cap: $5.23B
For an in-depth examination of LEGN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue